Ads
related to: fda approved statins
Search results
Results from the WOW.Com Content Network
Rosuvastatin is approved in the United States for the treatment of high LDL cholesterol (dyslipidemia), total cholesterol (hypercholesterolemia), and/or triglycerides (hypertriglyceridemia). [41] In February 2010, rosuvastatin was approved by the FDA for the primary prevention of cardiovascular events. [42]
Pitavastatin (usually as a calcium salt) is a member of the blood cholesterol lowering medication class of statins. [1] Pitavastatin is an inhibitor of HMG-CoA reductase, the enzyme that catalyses the first step of cholesterol synthesis. It was patented in 1987 and approved for medical use in 2003. [2] It is available in Japan, South Korea and ...
Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in the liver that plays a role in producing cholesterol. [6] Atorvastatin was patented in 1986, and approved for medical use in the United States in 1996. [6] [7] It is on the World Health Organization's List of Essential Medicines. [8]
Merck gained Food and Drug Administration approval for its powerful new cholesterol drug Liptruzet, a combination of two already-approved drugs, Pfizer's Lipitor and Merck's Zetia. Merck already ...
The U.S. Food and Drug Administration (FDA) notified healthcare professionals of updates to the prescribing information concerning interactions between protease inhibitors and certain statin drugs. Protease inhibitors and statins taken together may increase the blood levels of statins and increase the risk for muscle injury (myopathy).
The year-long clinical trial included people who were unable to lower their LDL cholesterol enough using statins. Lerodalcibep is not yet approved by the FDA, but two other drugs in this class ...
Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug.In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [1]
The U.S. Food and Drug Administration (FDA) granted the approval of Nexletol to Esperion Therapeutics. [2] [5] The FDA approved bempedoic acid based on evidence from two clinical trials (Trial 1/ NCT02666664 and Trial 2/NCT02991118) of 3009 subjects with high LDL cholesterol and known atherosclerotic cardiovascular disease or HeFH. [6]
Ads
related to: fda approved statins